Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Down 5.7% – Here’s What Happened

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s share price fell 5.7% during trading on Monday . The stock traded as low as $36.41 and last traded at $36.19. 266,106 shares traded hands during trading, a decline of 18% from the average session volume of 324,345 shares. The stock had previously closed at $38.37.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cantor Fitzgerald assumed coverage on Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an “overweight” rating and a $57.00 target price on the stock. Finally, Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Trading Down 1.3 %

The stock has a market cap of $2.18 billion, a price-to-earnings ratio of 36.90 and a beta of 0.90. The stock has a 50-day moving average price of $37.24 and a two-hundred day moving average price of $34.66.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. During the same quarter last year, the business posted ($0.29) EPS. The company’s revenue was up 14.2% on a year-over-year basis. Research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current fiscal year.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jack A. Khattar sold 125,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the transaction, the chief executive officer now directly owns 926,172 shares in the company, valued at $33,971,988.96. The trade was a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 164,390 shares of company stock worth $6,064,151 in the last ninety days. 9.30% of the stock is owned by insiders.

Institutional Trading of Supernus Pharmaceuticals

Large investors have recently modified their holdings of the business. Millennium Management LLC grew its position in Supernus Pharmaceuticals by 395.1% in the second quarter. Millennium Management LLC now owns 161,332 shares of the specialty pharmaceutical company’s stock worth $4,316,000 after buying an additional 128,743 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Supernus Pharmaceuticals by 7.6% in the second quarter. The Manufacturers Life Insurance Company now owns 26,554 shares of the specialty pharmaceutical company’s stock worth $710,000 after buying an additional 1,870 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Supernus Pharmaceuticals in the second quarter worth approximately $1,070,000. GAMMA Investing LLC grew its position in Supernus Pharmaceuticals by 97.1% in the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 398 shares during the last quarter. Finally, Exchange Traded Concepts LLC acquired a new position in Supernus Pharmaceuticals in the third quarter worth approximately $672,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.